Table 1 Demographic and disease-related characteristics among patients with or without ADRs (univariate logistic regression)
Characteristics | Â | Cases, n (%) | ADR | OR a (95%CI) | P value | |
|---|---|---|---|---|---|---|
With, (%) | Without, n (%) | |||||
All | Â | 485 (100) | 296 (61.0) | 189 (39.0) | Â | Â |
Age: Mean (SD) | Â | 63.4 (11.8) | 67.8 (12.6) | 59.5 (11.3) | Â | Â |
Age | ≥60 | 294 (60.6) | 202 (68.2) | 92 (48.7) | 3.247 [1.564–7.681] | 0.014* |
<60 | 191 (39.4) | 94 (31.8) | 97 (51.3) | 1 | Â | |
Sex | Male | 261 (53.8) | 161 (54.4) | 100 (52.9) | 1.014 [0.386–1.714] | 0.325 |
Female | 224 (46.2) | 135 (45.6) | 89 (47.1) | 1 | Â | |
Education Level | College and above | 155 (32) | 77 (26) | 78 (41.3) | 0.713 [0.431–0.950] | 0.017* |
High school and below | 330 (68) | 219 (74) | 111 (58.7) | 1 | Â | |
Place of residence | Urban | 194 (40) | 114 (38.5) | 80 (42.3) | 2.192 [0.689–5.237] | 0.189 |
Rural | 291 (60) | 182 (61.5) | 109 (57.7) | 1 | Â | |
Family income (Yuan)/M | >10,000 | 56 (11.5) | 35 (11.8) | 21 (11.1) | 1.885 [0.332–6.457] | 0.846 |
5001 ~ 10,000 | 227 (46.8) | 133 (44.9) | 94 (49.7) | 0.912 [0.420–1.518] | 0.092 | |
3001 ~ 5000 | 175 (36.1) | 113 (38.2) | 62 (32.8) | 3.817 [0.774–9.220] | 0.332 | |
<3000 | 27 (5.6) | 15 (5.1) | 12 (6.3) | 1 | Â | |
Primary cancer | Lung | 122 (25.2) | 88 (29.7) | 34 (18) | 3.892 [1.521–10.109] | 0.008** |
Renal | 86 (17.7) | 59 (19.9) | 27 (14.3) | 1.732 [0.458–6.256] | 0.122 | |
Gastric | 49 (10.1) | 22 (7.4) | 27 (14.3) | 3.069 [1.746–9.961] | 0.007** | |
Colorectal | 53 (11) | 23 (7.8) | 30 (15.9) | 3.549 [1.472–9.135] | 0.006** | |
Breast | 89 (18.4) | 59 (19.9) | 30 (15.9) | 1.776 [0.753–3.158] | 0.084 | |
Non-Hodgkin’s Lymphoma | 56 (11.5) | 34 (11.6) | 22 (11.6) | 4.711 [0.843–7.953] | 0.569 | |
Others | 30 (6.2) | 11 (3.7) | 19 (10) | 1 | Â | |
Medical insurance | Yes | 383 (79) | 231 (78) | 152 (80.4) | 3.791 [0.654–7.824] | 0.264 |
No | 102 (21) | 65 (22) | 37 (19.6) | 1 | Â | |
CCI | >2 | 240 (49.5) | 178 (60.1) | 62 (32.8) | 4.139 [1.418–7.027] | 0.003** |
≤2 | 245 (50.5) | 118 (39.9) | 127 (67.2) | 1 |  | |
Duration of medicine | ≤3 months | 262 (54) | 98 (33.1) | 164 (62.1) | 0.647 [0.463–0.815] | 0.004** |
>3 months | 223 (46) | 198 (66.9) | 25 (37.9) | 1 |  | |
Combination of medicine | Yes | 286 (59) | 201 (67.9) | 85 (45) | 1.736 [1.486–4.153] | 0.028* |
No | 199 (41) | 95 (32.1) | 104 (55) | 1 | Â | |
Route of administration | Intravenous | 209 (43.1) | 164 (55.4) | 45 (23.8) | 3.128 [2.066–7.550] | 0.007** |
Oral | 179 (36.9) | 100 (33.8) | 79 (41.8) | 1.806 [0.538–6.872] | 0.075 | |
Subcutaneous | 65 (13.4) | 25 (8.4) | 40 (21.2) | 1.257 [0.296–1.836] | 0.066 | |
Intrathecal | 7 (1.4) | 3 (1.0) | 4 (2.1) | 2.129 [0.588–4.967] | 0.125 | |
Intraperitoneal | 25 (5.2) | 4 (1.4) | 21 (1.1) | 1 | Â | |